Lab to Impact: Healthcare Module – From Bench to Market: Navigating the Complex Landscape of Drug Commercialization

Join the Center for Technology Licensing for a dynamic panel on the real-world path from innovation to therapeutic impact.

Industry leaders and biotech entrepreneurs, including Weill Cornell inventors and founders of licensed startup Convergent Therapeutics, will share an insightful discussion on navigating the path from the laboratory to the patient in the drug development space. Whether you’re considering commercialization or actively developing potential new drugs, this panel offers valuable perspectives on turning promising research into new therapies.

Our expert panelists will share practical insights from every stage of the process—from discovery and development, preclinical research, and clinical trials to FDA review and post-market safety monitoring. You’ll gain a better understanding of how regulatory strategy and market access shape the journey, and how successful teams overcome common barriers to bring therapeutics to market.

What to expect:

• Key insights into regulatory and market access strategy
• Lessons from successful therapeutic launches
• Real-world examples of collaboration and adaptation
• Expert perspectives across the full drug development lifecycle

Guest speakers: 

• Alexander Brown, COO of Convergent Therapeutics
• Dr. Neil Bander, CSO, Co-Founder of Convergent Therapeutics
• Dr. Philip Kantoff, CEO, Co-Founder of Convergent Therapeutics
• Dr. Scott Tagawa, Professor of Medicine in Urology at Weill Cornell Medicine 

Hosted by Brian Kelly, Director of Technology Licensing, CTL at Weill Cornell Medicine

Whether you’re considering a new idea, commercialization, or actively developing a technology, this event offers valuable perspectives on turning promising research into market-ready solutions.